Aurobindo Pharma Limited
MarketLine (a Datamonitor Company)
07 Jul 2015
Available for Immediate Download
Aurobindo Pharma Limited (APL) develops, manufactures and markets active pharmaceutical ingredients (APIs) and finished dosage formulations. The company develops product in the antibiotics, anti-retroviral, cardiovascular system (CVS), central nervous system (CNS), gastroenterological, anti-diabetics and anti-allergic areas. APL operates in Asia Pacific, Europe, South Africa, Australia and the Americas. It is headquartered in Hyderabad, India and employs around 9,500 people. The company recorded revenues of INR80,997.9 million (approximately $1,347.8 million) in the fiscal year ended March 2014, an increase of 38.3% over 2013. The company's operating profit was INR18,426.8 million (approximately $306.6 million) in fiscal 2014, as compared to an operating profit of INR6,407.5 million (approximately $106.6 million) in 2013. Its net profit was INR11,728.5 million (approximately $195.2 million) in fiscal 2014, as compared to the net profit of INR2,938.6 million (approximately $48.9 million) in 2013.